{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-225848","form_type":"8-K","ticker":"PROK","cik":"0001850270","company_name":"PROKIDNEY CORP.","filed_at":"2026-05-15T15:49:09+00:00","discovered_at":"2026-05-15T15:50:00.453314+00:00","generated_at":"2026-05-15T15:53:10.861472+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026","bullets":["Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.","Phase 3 PROACT 1 enrollment on track to complete mid-2026; pivotal topline results expected Q2 2027.","FDA confirmed eGFR slope as surrogate endpoint for accelerated approval under RMAT designation.","Phase 2 REGEN-007 showed 4.6 mL/min/1.73m² improvement in annual eGFR slope decline.","R&D expenses $33.8M (+24% YoY) driven by PROACT 1; G&A expenses $11.3M (-21% YoY)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-225848","json":"https://secwatch.observer/filing/0001193125-26-225848.json","markdown":"https://secwatch.observer/filing/0001193125-26-225848.md","text":"https://secwatch.observer/filing/0001193125-26-225848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/0001193125-26-225848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/prok-20260515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T15:53:10.861472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4038b4c9148840f1626c887001cd5f29ee23a952","claim":"PROKIDNEY CORP. reported the first quarter ended March 31, 2026 results: net income Net loss before noncontrolling interest was $42.6 million.","evidence_excerpt":"ProKidney Corp. (the \"Company\") issued a press release to announce its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1850270/000119312526225848/0001193125-26-225848-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss before noncontrolling interest was $42.6 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}